ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
36 hedge funds and large institutions have $4.67M invested in ImmunoCellular Therapeutics, Ltd. in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 9 closing their positions.
34% more capital invested
Capital invested by funds: $3.48M → $4.67M (+$1.19M)
4% more call options, than puts
Call options by funds: $705K | Put options by funds: $678K
8% less funds holding
Funds holding: 39 → 36 (-3)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$693K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$225K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$125K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$24.9K |
| 5 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$24.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$196K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$136K |
| 3 |
OC
Oppenheimer & Co
New York
|
-$119K |
| 4 |
DS
DRW Securities
Chicago,
Illinois
|
-$111K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$86.9K |
IMUC Hedge Fund Activity: Q1 2014 in Review
36 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q1 2014, worth a combined $4.67M — up 34% from $3.48M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IMUC and 6 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 7 added.
The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $693K. The largest seller was Group One Trading, exiting entirely with an estimated $196K sold.
- 36 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q1 2014, down from 39 in Q4 2013.
- Funds reported $4.67M of ImmunoCellular Therapeutics, Ltd. stock for Q1 2014, up 34% quarter-over-quarter.
- 6 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q1 2014 and 9 closed out, a net change of -3 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q1 2014 was DAFNA Capital Management, an estimated $693K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q1 2014 was Group One Trading, an estimated $196K sold.
Based on aggregated 13F filings for Q1 2014.